Cat. No.: HY-N0177

Diosgenin

Name: Diosgenin
Brand: MedChemExpress
SKU: HY-N0177
Price: 55.00 USD
Availability: InStock
Rating: 5 (11 reviews)

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway. Diosgenin is an exogenous activator of Pdia3/ERp57. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.

For research use only. We do not sell to patients.

Purity : 99.92%
CAS No.: 512-04-9
Formula: C₂₇H₄₂O₃
Molecular Weight:414.62

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Diosgenin Chemical Structure

CAS No.: 512-04-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Diosgenin, a steroidal saponin, can inhibit STAT3 signaling pathway^[1]. Diosgenin is an exogenous activator of Pdia3/ERp57^[2]. Diosgenin inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression^[5].

IC₅₀ & Target

^[1]

STAT3

All STAT Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μM Compound: 1	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
A549	IC₅₀	>20 μM Compound: a1	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
A549	IC₅₀	>20 μg/mL Compound: 9	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23511021]
A549	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
A549	IC₅₀	26.41 μM Compound: Diosgenin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
A549	IC₅₀	32.85 μM Compound: DSG; 1	Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
ASPC1	IC₅₀	63.11 μM Compound: Diosgenin	Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
BXPC-3	GI₅₀	1 μg/mL Compound: 7	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
DU-145	GI₅₀	8.5 μg/mL Compound: 7	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
GES1	IC₅₀	100.7 μM Compound: Diosgenin	Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HBL-100	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HBL100 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HCT-116	IC₅₀	31.41 μM Compound: Diosgenin	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
HCT-116	IC₅₀	49.11 μM Compound: Diosgenin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HeLa	IC₅₀	>50 μg/mL Compound: 21	Cytotoxicity against human HeLa cells after 6 days by SRB assay Cytotoxicity against human HeLa cells after 6 days by SRB assay	[PMID: 22880631]
Hep 3B2	IC₅₀	>20 μg/mL Compound: 9	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 23511021]
HepG2	IC₅₀	>10 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
HepG2	IC₅₀	>20 μg/mL Compound: 9	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 23511021]
HepG2	IC₅₀	>50 μM Compound: 1, Diosgenin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23153797]
HepG2	IC₅₀	33.87 μM Compound: Diosgenin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
HepG2	IC₅₀	48.36 μM Compound: DSG; 1	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
HL-60	IC₅₀	>20 μM Compound: a1	Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
HT-29	IC₅₀	>50 μg/mL Compound: 21	Cytotoxicity against human HT-29 cells after 6 days by SRB assay Cytotoxicity against human HT-29 cells after 6 days by SRB assay	[PMID: 22880631]
HT-29	IC₅₀	10.8 μM Compound: Diosgenin	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
K562	IC₅₀	>50 μg/mL Compound: 21	Cytotoxicity against human K562 cells after 6 days by SRB assay Cytotoxicity against human K562 cells after 6 days by SRB assay	[PMID: 22880631]
K562	IC₅₀	30.04 μM Compound: DSG; 1	Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
KM-20L2	GI₅₀	1.1 μg/mL Compound: 7	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
MCF7	GI₅₀	0.42 μg/mL Compound: 7	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	>10 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 33381964]
MCF7	IC₅₀	>20 μM Compound: a1	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
MCF7	IC₅₀	>20 μg/mL Compound: 9	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 23511021]
MCF7	IC₅₀	>50 μg/mL Compound: 21	Cytotoxicity against human MCF7 cells after 6 days by SRB assay Cytotoxicity against human MCF7 cells after 6 days by SRB assay	[PMID: 22880631]
MCF7	IC₅₀	23.91 μM Compound: Diosgenin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 31761382]
MCF7	IC₅₀	28.52 μM Compound: DSG; 1	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MDA-MB-231	IC₅₀	>20 μg/mL Compound: 9	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 23511021]
MDA-MB-231	IC₅₀	>50 μM Compound: 1, Diosgenin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23153797]
MKN-45	IC₅₀	78.32 μM Compound: DSG; 1	Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MNK45 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
MM96L	IC₅₀	>50 μg/mL Compound: 21	Cytotoxicity against human MM96L cells after 6 days by SRB assay Cytotoxicity against human MM96L cells after 6 days by SRB assay	[PMID: 22880631]
NCI-H358	IC₅₀	>40 μM Compound: Diosgenin	Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
NCI-H460	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NCI-H460	IC₅₀	>50 μM Compound: 1	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
NFF	IC₅₀	>50 μg/mL Compound: 21	Cytotoxicity against human NFF cells after 6 days by SRB assay Cytotoxicity against human NFF cells after 6 days by SRB assay	[PMID: 22880631]
P388	ED₅₀	>10 μg/mL Compound: 7	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
SF-268	GI₅₀	1.6 μg/mL Compound: 7	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SMMC-7721	IC₅₀	>20 μM Compound: a1	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW480	IC₅₀	>20 μM Compound: a1	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 30822712]
SW-620	IC₅₀	>40 μM Compound: Diosgenin	Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 35586422]
T-24	IC₅₀	28.85 μM Compound: DSG; 1	Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay Cytotoxicity against human T24 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 assay	[PMID: 33740546]
THP-1	IC₅₀	6.96 μM Compound: 2	Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs Anticoagulant activity in human THP1 cells assessed as inhibition of TNF-alpha-stimulated tissue factor expression incubated 1 hr before TNFalpha challenge measured after 5 hrs	[PMID: 20561785]

In Vitro

In MC65 cells, a cellular AD model, diosgenin exhibited weak protective abilities at 1 μM, may represent a good candidate as a steroidal moiety in our bivalent compounds against AD pathology^[3]. Diosgenin inhibits the constitutive activation of STAT3 in C3A cells in a dose-dependent manner, with maximum inhibition occurring at around 100 μM^[1].
Diosgenin (10 μM; 24 h) significantly decreases the levels of miR-19b in foam cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Diosgenin treatment significantly reduces fasted and refed blood glucose level in HF dietfed mice. Diosgenin treatment significantly reduces blood glucose level in IPGTT test, compared with that of HF diet-fed mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS No. 512-04-9
Appearance Solid
Molecular Weight 414.62
Formula C₂₇H₄₂O₃
Color White to off-white
SMILES

O[C@]1([H])CC2=CC[C@]3([H])[C@@](CC[C@@]4(C)[C@@]3([H])C[C@@]5([H])[C@]4([H])[C@@](C)([H])[C@@]6(CC[C@@]([H])(C)CO6)O5)([H])[C@@]2(C)CC1
Structure Classification
- Steroids
Initial Source
- Plant
- Other Families Extract
- Endogenous metabolite
- Human Gut Microbiota Metabolites
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (11)

All RT-PCRWBCell Imaging/StainingCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

J Biomed Sci

Dietary diosgenin transcriptionally down-regulated intestinal NPC1L1 expression to prevent cholesterol gallstone formation in mice. [Abstract]

2023 Jun 27;30(1):44. PMID: 37370162

Diosgenin purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2023 Jun 27;30(1):44. [Abstract]

mRNA expression of genes in Caco2 cells under Diosgenin (5, 10 μM) treatment.

Diosgenin purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2023 Jun 27;30(1):44. [Abstract]

Protein level of NPC1L1 in Caco2 cell treated with Diosgenin (5, 10 μM) or cholesterol.

Diosgenin purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2023 Jun 27;30(1):44. [Abstract]

Fluorescence image of cholesterol uptake in Caco2 cells under NBD-cholesterol containing medium with and without Diosgenin (10 μM) and ezetimibe.
Phytomedicine

Diosgenin exerts dual impacts on Th17 cell differentiation in adjuvant-induced arthritis rats by impairing SIRT1-mediated deacetylation. [Abstract]

2025 Nov 25:148:157384. PMID: 41101071
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Diosgenin as a substitute for cholesterol alleviates NAFLD by affecting CYP7A1 and NPC1L1-related pathway. [Abstract]

2024 Mar:125:155299. PMID: 38301301
J Pharm Anal

2026 Apr 13.
Pharmaceuticals (Basel)

Neuroprotective Effects of Qi Jing Wan and Its Active Ingredient Diosgenin Against Cognitive Impairment in Plateau Hypoxia. [Abstract]

2025 May 17;18(5):738. PMID: 40430556
Chem Biol Interact

Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammation. [Abstract]

2025 Jan 5:405:111306. PMID: 39536891
Chin J Integr Med

Diosgenin Attenuates Angiogenesis via Targeting Src/STAT3 Signaling Pathway to Treat Non-Small Cell Lung Cancer. [Abstract]

2026 Feb 14. PMID: 41689610
Biochem Biophys Res Commun

Diosgenin improves post-myocardial infarction cardiac function via HAND2-induced angiogenesis. [Abstract]

2024 Jun 18:712-713:149941. PMID: 38643718
Cell Physiol Biochem

Ca2+ Entry, Oxidative Stress, Ceramide and Suicidal Erythrocyte Death Following Diosgenin Treatment. [Abstract]

2016;39(4):1626-37. PMID: 27626275

Diosgenin purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2016;39(4):1626-37. [Abstract]

Arithmetic means ± SEM (n = 10) of erythrocyte annexin-V-binding following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) Diosgenin (5-15 µM).
Authorea

May 12, 2022.

Solvent & Solubility

In Vitro:

Ethanol : 3.33 mg/mL (8.03 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4118 mL

12.0592 mL

24.1185 mL

5 mM

0.4824 mL

2.4118 mL

4.8237 mL

10 mM

---

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (6.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (6.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 0.67 mg/mL (1.62 mM); Clear solution

This protocol yields a clear solution of ≥ 0.67 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (6.7 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 2.5 mg/mL (6.03 mM); Suspended solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 15% Solutol HS 15 10% Cremophor EL 35% PEG400 40% Water

Solubility: 10.31 mg/mL (24.87 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li F, et al. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010 Jun 28;292(2):197-207. [Content Brief]

[2]. Tohda C, et al. Diosgenin is an exogenous activator of 1,25D₃-MARRS/Pdia3/ERp57 and improves Alzheimer's disease pathologies in 5XFAD mice. Sci Rep. 2012;2:535. [Content Brief]

[3]. Jeremy E. Chojnacki, et al. Bivalent ligands incorporating curcumin and diosgenin as multifunctional compounds against Alzheimer’s disease. Bioorganic & Medicinal Chemistry, 23 (2015) 7324–7331 [Content Brief]

[4]. Wang X, et al. Effect of diosgenin on metabolic dysfunction: Role of ERβ in the regulation of PPARγ. Toxicol Appl Pharmacol. 2015 Dec 1;289(2):286-96. [Content Brief]

[5]. Yun-cheng Lv, et al. Diosgenin Inhibits Atherosclerosis via Suppressing the MiR-19b-induced Downregulation of ATP-binding Cassette Transporter A1. Atherosclerosis, 2014, 240(1), 80-89.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol	1 mM	2.4118 mL	12.0592 mL	24.1185 mL	60.2962 mL
Ethanol	5 mM	0.4824 mL	2.4118 mL	4.8237 mL	12.0592 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Diosgenin

Publications Citing Use of MedChemExpress (MCE) Diosgenin

All STAT Isoforms